These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 1676283)
1. Lymphocytes from HIV-infected individuals show aberrant inositol polyphosphate metabolism which reverses after zidovudine therapy. Nye KE; Knox KA; Pinching AJ AIDS; 1991 Apr; 5(4):413-7. PubMed ID: 1676283 [TBL] [Abstract][Full Text] [Related]
2. The defect seen in the phosphatidylinositol hydrolysis pathway in HIV-infected lymphocytes and lymphoblastoid cells is due to inhibition of the inositol 1,4,5-trisphosphate 1,3,4,5-tetrakisphosphate 5-phosphomonoesterase. Nye KE; Riley GA; Pinching AJ Clin Exp Immunol; 1992 Jul; 89(1):89-93. PubMed ID: 1321014 [TBL] [Abstract][Full Text] [Related]
3. Trend towards decreased survival in patients infected with HIV resistant to zidovudine. Gøtzsche PC; Nielsen C; Gerstoft J; Nielsen CM; Vestergaard BF Scand J Infect Dis; 1992; 24(5):563-5. PubMed ID: 1361240 [TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466 [TBL] [Abstract][Full Text] [Related]
5. HIV infection of H9 lymphoblastoid cells chronically activates the inositol polyphosphate pathway. Nye KE; Pinching AJ AIDS; 1990 Jan; 4(1):41-5. PubMed ID: 1969281 [TBL] [Abstract][Full Text] [Related]
6. Long-term zidovudine therapy in patients with AIDS and symptomatic and asymptomatic HIV infection. Ebert S; Gockel K; Horowitz S; Weber P; Vogelman B; Graziano F Wis Med J; 1991 Apr; 90(4):161-5. PubMed ID: 1675028 [TBL] [Abstract][Full Text] [Related]
7. T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS. Levacher M; Tallet S; Dazza MC; Dournon E; Rouveix B; Pocidalo JJ Clin Exp Immunol; 1990 Aug; 81(2):177-82. PubMed ID: 1696859 [TBL] [Abstract][Full Text] [Related]
8. Augmentation of cellular immune function during the early phase of zidovudine treatment of AIDS patients. Rinaldo C; Huang XL; Piazza P; Armstrong J; Rappocciolo G; Pazin G; McMahon D; Gupta P; Fan Z; Zhang Z J Infect Dis; 1991 Oct; 164(4):638-45. PubMed ID: 1680135 [TBL] [Abstract][Full Text] [Related]
9. Zidovudine for early human immunodeficiency virus (HIV) infection: who, when, and how? Ruedy J; Schechter M; Montaner JS Ann Intern Med; 1990 May; 112(10):721-3. PubMed ID: 1970465 [No Abstract] [Full Text] [Related]
10. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Choi S; Lagakos SW; Schooley RT; Volberding PA Ann Intern Med; 1993 May; 118(9):674-80. PubMed ID: 8096373 [TBL] [Abstract][Full Text] [Related]
11. Population dynamics of HIV within an individual after treatment with zidovudine. McLean AR; Emery VC; Webster A; Griffiths PD AIDS; 1991 May; 5(5):485-9. PubMed ID: 1677807 [TBL] [Abstract][Full Text] [Related]
12. Zidovudine in asymptomatic HIV infection. Berger PB N Engl J Med; 1993 Dec; 329(25):1895; author reply 1895-6. PubMed ID: 7902534 [No Abstract] [Full Text] [Related]
13. T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. Ranki A; Mattinen S; Yarchoan R; Broder S; Ghrayeb J; Lähdevirta J; Krohn K AIDS; 1989 Feb; 3(2):63-9. PubMed ID: 2496721 [TBL] [Abstract][Full Text] [Related]
14. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115 [TBL] [Abstract][Full Text] [Related]
15. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651 [TBL] [Abstract][Full Text] [Related]
16. Oocyte activation and latent HIV-1 reactivation: AMPK as a common mechanism of action linking the beginnings of life and the potential eradication of HIV-1. Finley J Med Hypotheses; 2016 Aug; 93():34-47. PubMed ID: 27372854 [TBL] [Abstract][Full Text] [Related]
17. [Results of zidovudine treatment of 9 vertically HIV infected children]. Berkefeld I; Fuchs A; Wahn V Monatsschr Kinderheilkd; 1993 Jun; 141(6):498-504. PubMed ID: 8101636 [TBL] [Abstract][Full Text] [Related]
18. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611 [TBL] [Abstract][Full Text] [Related]
19. Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population-based cohort. Longini IM; Clark WS; Karon JM Am J Epidemiol; 1993 Jun; 137(11):1229-40. PubMed ID: 8100682 [TBL] [Abstract][Full Text] [Related]
20. When should asymptomatic patients with HIV infection be treated with zidovudine? Gazzard BG BMJ; 1992 Feb; 304(6825):456-7. PubMed ID: 1347712 [No Abstract] [Full Text] [Related] [Next] [New Search]